Spironolactone has been shown beneficial in CHF and many of the same mechanisms are at plan in RV failure from pulmonary hypertension.
Again, no clear evidence whether this is a useful treatment or not, and no evidence to guide... more »
Microvascular ischemia is common, particularly in the setting of critical illness. We need better ways to evaluate, diagnose and treat these conditions, whether they relate to microvascular myocardial ischemia, as a primary diagnosis of complication of other acute illness, or non-myocardial ischemia during the course of surgery, injury, infection or acute illness.
A comprehensive research plan is needed to identify the vascular causes of cognitive decline, to develop early treatment options, and most ideally, develop effective measures to maintain cognitive function.
Does interrupted or aberrant pulmonary vascular development contribute to pulmonary hypertension?
How can we develop new approaches to improve vascular healing and extend the long term benefits of vascular interventions for more patients?
Why loss of endoglin causes HHT is not known. Endoglin is expressed by vascular smooth muscle cells and endothelial cells.
What is the role of endogin on vascular smooth muscle cells and why its loss contributes to HHT and other vascular malformations
Does screening for asymptomatic vascular disease increase awareness, promote compliance with lifestyle interventions, and improve overall health?
How can we better model human vascular disease in all its complexity?
This is key to more effective translation of both diagnostics and therapeutics. Develop improved animal models of vascular diseases including PAD, aneurysm, venous diseases, to facilitate fundamental research and preclinical development.
What are the causative factors underlying the disparity in prevalence and progression of various vascular disorders (PAD, CVD, aneurysm) across populations?